Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL Stroke: Intensive vs Standard Blood Pressure Control in Stroke Patients
NCT04036409Completed
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Aug 2019
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of indapamide, perindopril and amlodipine in ischemic stroke, Transient Ischemic Attack (TIA) and hypertension (HTN) (2 arms), sponsored by Hospital Israelita Albert Einstein. Primary endpoint: Time to cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure at 3.5 years. Started Aug 2019; status: completed.
02
Drugs
indapamideperindoprilamlodipine
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)hypertension (HTN)
Beyond the preview
Go deeper on NCT04036409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04036409.